No matter whether patients had CAD or not, the simpler regimen was linked to less mortality and major bleeding at 6 months.

The data thus far suggest fewer repeat interventions with the newly FDA approved resorbable device compared with PTA.

WASHINGTON, DC—How patients weigh the opinions of their family and friends when making decisions about PAD varies by sex and ...

WASHINGTON, DC—For vascular closure after transfemoral TAVI, a strategy that combines suture- and plug-based devices halves ...

Fewer rehospitalizations and better functional and QoL outcomes point to TAVI as a good choice, but longer-term data are ...

The trial adds much-needed randomized data to an area where it’s been lacking. Questions about methods muddy interpretation.

Ami Bhatt and Michael Mack explore the ethics of AI use in the detection of subclinical cardiovascular disease.

The data hint at sirolimus becoming a useful option or even a replacement for paclitaxel, but full 5-year follow-up is needed ...

Select patients with moderate AS may benefit, but in general it’s okay to wait for severe stenosis, Nicolas Van Mieghem says.

With further refinement and defined thresholds for treatment, this technology has the potential to guide treatment decisions.

Conference news filled our list this month, dominated by TCT 2024, although two EACTS stories also cracked our top 10.

Ami Bhatt and Michael Mack explain the economics of AI use in the detection of subclinical cardiovascular disease.